产品名称

ABT 199 - GDC 0199 | Venetoclax

产品货号

Axon 2141 CAS [1257044-40-8] MF C45H50ClN7O7SMW 868.44 Purity: 98% Soluble in DMSO Description A highly potent, orally bioavailable BCL-2-selective inhibitor; a new Bcl-2–specific BH3 mimetic efficacious in vivo against mouse lymphomas without provoking thrombocytopenia. KEYWORDS: ABT 199 | supplier | Bcl-2 inhibitor | GDC 0199 | Venetoclax | ABT199 | GDC0199 | ABT-199 | GDC-0199 | CAS [1257044-40-8] | Non Selective | Bcl | Inhibitor | Proteins

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

ABT 199 - GDC 0199 | Venetoclax

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2141

CAS [1257044-40-8]

MF C45H50ClN7O7S
MW 868.44

Purity: 98%
Soluble in DMSO

ABT 199

Description

A highly potent, orally bioavailable BCL-2-selective inhibitor; a new Bcl-2–specific BH3 mimetic efficacious in vivo against mouse lymphomas without provoking thrombocytopenia.

KEYWORDS: ABT 199 | supplier | Bcl-2 inhibitor | GDC 0199 | Venetoclax | ABT199 | GDC0199 | ABT-199 | GDC-0199 | CAS [1257044-40-8] | Non Selective | Bcl | Inhibitor | Proteins

AJ Souers et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19(2), 202-208.

C Touzeau et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia advance online publication 16 August 2013; doi: 10.1038/leu.2013.216.

CJ Vandenberg and S Cory. ABT-199, a new Bcl-2–specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood, 2013, 121(12), 2285-2288.

Potent, orally bioavailable BCL-2-selective inhibitor

Chemical name

2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide

Parent CAS No.

[1257044-40-8]

产品资料